Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenxbio (RGNX) Net Income towards Common Stockholders (2016 - 2025)

Regenxbio has reported Net Income towards Common Stockholders over the past 12 years, most recently at -$67.2 million for Q4 2025.

  • For Q4 2025, Net Income towards Common Stockholders fell 31.01% year-over-year to -$67.2 million; the TTM value through Dec 2025 reached -$194.0 million, up 14.66%, while the annual FY2025 figure was -$194.0 million, 14.59% up from the prior year.
  • Net Income towards Common Stockholders for Q4 2025 was -$67.2 million at Regenxbio, down from -$62.0 million in the prior quarter.
  • Over five years, Net Income towards Common Stockholders peaked at $294.0 million in Q4 2021 and troughed at -$76.7 million in Q1 2022.
  • A 5-year average of -$27.8 million and a median of -$61.9 million in 2023 define the central range for Net Income towards Common Stockholders.
  • On a YoY basis, Net Income towards Common Stockholders climbed as much as 735.85% in 2021 and fell as far as 764.37% in 2021.
  • Year by year, Net Income towards Common Stockholders stood at $294.0 million in 2021, then decreased by 25.04% to $220.4 million in 2022, then crashed by 128.57% to -$63.0 million in 2023, then rose by 18.58% to -$51.3 million in 2024, then crashed by 31.01% to -$67.2 million in 2025.
  • Business Quant data shows Net Income towards Common Stockholders for RGNX at -$67.2 million in Q4 2025, -$62.0 million in Q3 2025, and -$70.9 million in Q2 2025.